News

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?
We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...
Medical Dialogues13h
Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...
Bristol-Myers Squibb Company: Markey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success
PRINCETON, NJ / ACCESS Newswire / June 6, 2025 / Originally published on University of Kentucky Research NewsA groundbreaking lung cancer screening project co-led by the University of Kentucky Markey ...
Medical Marketing & Media4h
The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more
Brian Peters started his new role as SVP of the AI Squared division at Apimeds Pharmaceuticals. Pharma market research firm Konovo named Tim Albury as CFO. Tenpoint Therapeutics announced the ...
Fierce Pharma3d
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...
BioWorld3d
Biontech trades half of bispecific BNT-327 to BMS for potential $11B+
Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...
BioNTech-Aktie steigt - Bristol zahlt bis zu $11,1 Mrd. in Krebsmedikament-Deal
Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines ...
Plant Services4d
Factory fallout: Manufacturing plant closures and layoffs from Jeld-Wen, Bristol Myers Squibb, Wabash, and more
Companies are navigating a delicate balance between cost-cutting and staying ahead in a changing manufacturing economy.